| Today’s Big NewsFeb 27, 2025 |
| By Nick Paul Taylor Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeutics before reaching the clinic. Verve, which attributed Vertex’s action to its changing R&D priorities, is taking the program forward independently having regained full rights to the asset. |
|
|
|
By Darren Incorvaia The Department of Health and Human Services is re-evaluating a $590 million contract for avian influenza mRNA vaccines that the prior administration struck with Moderna, according to a report in Bloomberg. The move comes as bird flu continues to spread throughout chickens and dairy cows, occasionally jumping into humans as well. |
By Darren Incorvaia Even as President Donald Trump wages a very public fight against diversity, equity and inclusion initiatives in the government and beyond, several large drugmakers say running diverse clinical trials is not optional or extraneous, but a core part of the work they do. |
Sponsored by Sciensus Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, and regulatory hurdles. |
|
Do you have the instrumentation & experts you need and simply require access to an expansive collection of biospecimens? Or are you in need of an experienced CRO? Either way, BioIVT has you covered! View Options >>
|
|
By Nick Paul Taylor Kallyope has slipped out results from a phase 2 trial of its obesity candidates, linking the combination of the two oral prospects to weight loss of 2.9% after 13 weeks of treatment. |
Sponsored by Fortrea Fortrea's CTO discusses AI's expanding role in clinical trials, from discovery to execution, and its potential to improve patient outcomes and diversity. |
By James Waldron Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in hepatitis B while it seeks a suitable partner. |
By James Waldron “While we remain confident in our zerlasiran program for high Lp(a), we will only initiate the phase 3 cardiovascular outcomes study once a partner is secured,” Silence CEO Craig Tooman said. |
By Eric Sagonowsky Disruptions to government-sanctioned advisory committee meetings on vaccines are becoming increasingly common after the recent confirmation of Robert F. Kennedy Jr. as secretary of the Department of Health and Human Services. |
By Fraiser Kansteiner After receiving a rare pediatric disease priority review voucher in tandem with Miplyffa’s FDA green light in September, Zevra has locked in a deal to sell the voucher for $150 million. The cash from the sale will be used to fuel R&D, plus the commercial rollouts of Miplyffa and the urea cycle disorder medicine Olpruva, which Zevra picked up in its $91 million buyout of Acer Therapeutics, the company said. |
By Darren Incorvaia Clinical trial matchmaker myTomorrows has struck up a partnership with personal health recordkeeper Patients Know Best so that U.K. participants with unmet medical needs can search for possible trials to join. |
By Emma Beavins The initiative, laid out in an executive order, aims to tightly leash agency spending by manually reviewing expenditures. |
By Conor Hale Kestra's vest-like Assure cardioverter defibrillators have been worn by more than 17,000 patients since its launch in August 2022. It aims to join the Nasdaq under the ticker KTMS. |
Fierce podcastsDon’t miss an episode |
| | Senior Editor Heather Landi, Senior Writer Paige Minemyer and Staff Writer Emma Beavins reflect on their trip to the ViVE conference in Nashville and what they learned. |
|
|---|
|
|
| Whitepaper This paper reviews key developments in the oncology market during 2024 and outlines what they mean for the future. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
